Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.56 |
| ▸ | CA2 | P00918 | 2/20 | 0.56 |
| ▸ | CA7 | P43166 | 2/20 | 0.56 |
| ▸ | CA9 | Q16790 | 2/20 | 0.56 |
| ▸ | CA6 | P23280 | 1/20 | 0.56 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7969768 | 0.95 | CA1 (0.50) | CA1CA2CA7CA9CA6 | |
| SCHEMBL10022350 | 0.81 | POLB (0.58) | CA1CA2CA7CA9CA6 | |
| SCHEMBL1030597 | 0.81 | CA1 (0.66) | CA1CA2CA7CA9CA6 | |
| SCHEMBL8358594 | 0.81 | CA1 (0.61) | CA1CA2CA7CA9CA6 | |
| Hydrochloric Acid SCHEMBL3544398 | 0.79 | CA1 (0.64) | CA1CA2CA7CA9CA6 | |
| SCHEMBL15683644 | 0.79 | CA1 (0.59) | CA1CA2CA7CA9CA6 | |
| SCHEMBL24720999 | 0.78 | PHGDH (0.47) | CA1CA2CA7CA9CA6 | |
| SCHEMBL25845301 | 0.77 | CA1 (0.61) | CA1CA2CA7CA9CA6 | |
| SCHEMBL31195399 | 0.77 | CA1 (0.61) | CA1CA2CA7CA9CA6 | |
| SCHEMBL8262169 | 0.77 | CA1 (0.61) | CA1CA2CA7CA9CA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009144450-A1 | TETRAHYDROFURO [3, 2-B] PYRROL-3-ONE DERIVATIVES AS INHIBITORS OF CYSTEINE PROTEASES | AMURA THERAPEUTICS LIMITED (GB) | 2009-12-03 | — | — | WO | disclosed |
| US-20090270360-A1 | DICARBOXAMIDE DERIVATIVES | BOEHRINGER MARKUS | 2009-10-29 | — | — | US | disclosed |
| US-7501413-B2 | Dicarboxamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270360-A1 | DICARBOXAMIDE DERIVATIVES | F2, F12, TFPI | CA1 280/4885CA2 77/4885CA7 164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.